Cronos Group (TSE:CRON) Shares Down 0.8% – Should You Sell?

Cronos Group Inc. (TSE:CRONGet Free Report) shares fell 0.8% during trading on Tuesday . The company traded as low as C$3.84 and last traded at C$3.89. 83,617 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 169,685 shares. The stock had previously closed at C$3.92.

Wall Street Analysts Forecast Growth

Separately, TD lifted their price target on Cronos Group from C$4.50 to C$5.50 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of C$4.75.

Get Our Latest Report on Cronos Group

Cronos Group Price Performance

The firm has a market capitalization of C$1.45 billion, a P/E ratio of -188.00, a PEG ratio of 0.12 and a beta of 1.13. The business’s 50-day simple moving average is C$3.81 and its 200 day simple moving average is C$3.67. The company has a quick ratio of 24.01, a current ratio of 21.87 and a debt-to-equity ratio of 0.12.

Cronos Group (TSE:CRONGet Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported C$0.06 earnings per share for the quarter. Cronos Group had a negative net margin of 1.29% and a negative return on equity of 0.19%. The firm had revenue of C$62.86 million during the quarter. Sell-side analysts forecast that Cronos Group Inc. will post -0.26 earnings per share for the current year.

About Cronos Group

(Get Free Report)

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.

Featured Stories

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.